Factor XI Inhibition: Understanding Trial Data

Description

Learner Objective

Upon completion of this activity, you should be able to:

Explain DOACs and Factor XI inhibitors’ implications for thromboembolic risk and bleeding profile.
Evaluate clinical trial data on the safety and efficacy of FXI inhibitors in various cardiovascular conditions, including AF, ACS, and stoke.

Faculty

Geoffrey D. Barnes, MD, MSc, FACC
University of Michigan
Disclosures
Consultant Fees/Honoraria: Anthos, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis
Research/Research Grants: Blue Cross Blue Shield of Michigan, Boston Scientific

Peer Reviewers
Geoffrey D. Barnes, MD, MSc, FACC
University of Michigan
Disclosures
Consultant Fees/Honoraria: Anthos, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis
Research/Research Grants: Blue Cross Blue Shield of Michigan, Boston Scientific

Deborah Michelle Siegal, MD
University of Ottowa
Disclosures
Consultant Fees/Honoraria: Leo Pharma, Perosphere, VarmX

Chris Owen, MS, APRN, ACNP-BC, RNFA, FACC

Nurse Planner
American College of Cardiology

Disclosures
Consultant Fees/Honoraria: SilkRoad

Grant Acknowledgement
Educational grant support for this activity provided by: Bristol Myers Squibb and Janssen Pharmaceuticals, Inc., Alliance.

Summary

Availability:

On-Demand

Access expires on May 01, 2027

Cost:

FREE

Credit Offered:

0.5 CME Credit

0.5 CNE Credit

0.5 AAPA Credit

0.5 ABIM-MOC Point

0.5 IPCE Credit